Answers are grounded in this paper and cite their sources.
A new sustained-release (SR) pregabalin tablet, YHD1119, was formulated for once-daily dosing.In the current study, we aimed to evaluate the pharmacokinetics of YHD1119 tablets in patients with reduced renal function.Subjects were grouped by creatinine clearance: > 60 mL/min/1.73m 2 (Cohort A) and 30-60 mL/min/1.73m 2 (Cohort B).Eight subjects in Cohort A received a YHD1119 75 mg tablet (Y75T) and a YHD1119 150 mg tablet (Y150T) in each period, and eight subjects in Cohort B received a Y75T.Non-compartment analysis and population pharmacokinetic analysis using a one-compartment model with first-order elimination and first-order absorption with lag time were performed.Sixteen subjects completed the study.The geometric mean ratio (GMR) (90% confidence intervals [CI]) for maximum concentration (C max ), and area under the concentration-time profile from 0 to the last measurable time (AUC last ) after Y75T of Cohort B to those of Y75T of Cohort A were 1.2273 (1.0245-1.4701),and 2.4146 (1.8142-3.2138),respectively.The GMR (90% CI) for C max , and AUC last after Y75T of Cohort B to those of Y150T of Cohort A were 0.6476 (0.5229-0.8021), and 1.1471 (0.8418-1.5632), respectively.Simulated steady-steady pregabalin concentrations after once-daily Y75T dosing in subjects with eGFR 45 mL/min/1.73m 2 were within the range of steady-state concentrations simulated after once-daily Y150T dosing in subjects with eGFR 90 mL/min/1.73m 2 .The total pregabalin exposure of Y75T in patients with moderate renal impairment was comparable with that of Y150T in subjects with near-normal renal function.
No takes yet. Share an insight, caveat, or question.
Park et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: